Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced that it has closed on its previously announced registered direct offering. The company transacted the closing with a single healthcare-focused institutional investor; the closing consisted of the purchase and sale of 1,585,350 shares of common stock (or common stock equivalents in lieu thereof), which were made available at a purchase price of $1.22 per share. In addition, the company also transacted a concurrent private placement, which included the issuance of unregistered warrants to purchase up to 3,170,700 shares of common stock; those shares had an exercise price of $0.86 per share and are immediately exercisable for a period of three years following issuance. The company noted that H.C. Wainwright & Co. acted as the exclusive placement agent for the offering, which resulted in gross proceeds of an estimated $1.9 million. According to the announcement, the company anticipates using the funds for working capital and other general corporate purposes.
To view the full press release, visit https://ibn.fm/Veg5Q
About Aditxt Inc.
Aditxt is a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system. The company’s mission of “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders that inform and inspire. Aditxt’s diverse innovation portfolio includes Adimune Inc.(TM), developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir Inc.(TM), focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta Inc.(TM), which offers personalized immune monitoring for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy. For more information, please visit www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork